Plain-English translation of NCT05635162 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing plus — two drugs given together — to see if treating slow-growing mantle cell lymphoma early and then stopping after 6 months works well and is safe. You would be randomly assigned to either receive this medication combination for 6 months, or to be closely watched without treatment. Everyone in the trial will be followed for at least 2 years to see how well the treatment works.
Doctors are not sure whether people with slow-growing mantle cell lymphoma should start treatment right away or wait until symptoms get worse. This trial will help answer that question and see if this new medication combination is effective and safe for early treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one group will take the medication combination for 6 months (6 cycles of 28 days each), and the other group will be watched closely without treatment. Both groups will have regular clinic visits and scans to check your health, and you will be followed for at least 2 years after joining. If your lymphoma gets worse and you are in the observation group, you will receive standard treatment at that time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United Kingdom